Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Eflornithine |
Synonyms | |
Therapy Description |
Eflornithine is an ornithine decarboxylase inhibitor that blocks polyamine production, resulting in reduced tumor cell proliferation (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Eflornithine | DFMO|alpha-difluoromethylornithine | Eflornithine is an ornithine decarboxylase inhibitor that blocks polyamine production, resulting in reduced tumor cell proliferation (PMID: 32256343). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03581240 | Expanded access | Eflornithine | An Intermediate Expanded Use Trial of DFMO | Available | USA | 0 |
NCT02559778 | Phase I | Bortezomib Crizotinib Lapatinib Vorinostat Eflornithine Sorafenib Dasatinib | Pediatric Precision Laboratory Advanced Neuroblastoma Therapy | Recruiting | USA | 0 |
NCT02139397 | Phase Ib/II | Eflornithine Bortezomib | Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma | Active, not recruiting | USA | 0 |